Pursuant to the Regulation 30 of SEBI (LODR) Regulation, 2015 revised Corporate disclosure as enclosed.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shricon Industries Ltd has received two drug wholesale distribution licenses from the Food Safety and Drug Control Commissionerate, Government of Rajasthan, both dated July 15, 2025. The licenses (Nos. DRUG/2025-26/136520 and DRUG/2025-26/136521) allow the company to sell, stock and distribute drugs including those specified in Schedules C and C(1) (excluding Schedule X) from its premises at Shakti Nagar, Kota. The company states these licenses enable it to expand into the pharmaceutical, nutraceuticals and ayurveda sectors. The licenses are valid perpetually subject to payment of a retention fee every five years. Sheetal Jain is named as the qualified person in charge. No financial impact or revenue estimate has been disclosed.
This is a positive development as it opens a new business vertical (pharma, nutraceuticals, ayurveda) for the company, potentially creating a new revenue stream. However, since no financial impact or revenue guidance has been provided, the immediate effect on the stock price is likely to be modest.